These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12097259)

  • 1. Transactivation-deficient DeltaTA-p73 acts as an oncogene.
    Stiewe T; Zimmermann S; Frilling A; Esche H; Pützer BM
    Cancer Res; 2002 Jul; 62(13):3598-602. PubMed ID: 12097259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative TP73 transcript analysis in hepatocellular carcinomas.
    Stiewe T; Tuve S; Peter M; Tannapfel A; Elmaagacli AH; Pützer BM
    Clin Cancer Res; 2004 Jan; 10(2):626-33. PubMed ID: 14760085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.
    Stiewe T; Theseling CC; Pützer BM
    J Biol Chem; 2002 Apr; 277(16):14177-85. PubMed ID: 11844800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.
    Sayan AE; Sayan BS; Findikli N; Ozturk M
    Oncogene; 2001 Aug; 20(37):5111-7. PubMed ID: 11526499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression.
    Tuve S; Wagner SN; Schittek B; Pützer BM
    Int J Cancer; 2004 Jan; 108(1):162-6. PubMed ID: 14618632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of p73 in malignancy: tumor suppressor or oncogene?
    Stiewe T; Pützer BM
    Cell Death Differ; 2002 Mar; 9(3):237-45. PubMed ID: 11859406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.
    Petrenko O; Zaika A; Moll UM
    Mol Cell Biol; 2003 Aug; 23(16):5540-55. PubMed ID: 12897129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
    Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
    Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
    Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
    Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression but lack of mutation and methylation of p73 in hepatocellular carcinoma.
    Pan H; Liao SJ; Lai WY; Lu HC; Hsiao KM
    Acta Oncol; 2002; 41(6):550-5. PubMed ID: 12546528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p73 supports cellular growth through c-Jun-dependent AP-1 transactivation.
    Vikhanskaya F; Toh WH; Dulloo I; Wu Q; Boominathan L; Ng HH; Vousden KH; Sabapathy K
    Nat Cell Biol; 2007 Jun; 9(6):698-705. PubMed ID: 17496887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells.
    Tomkova K; Belkhiri A; El-Rifai W; Zaika AI
    Cancer Res; 2004 Sep; 64(18):6390-3. PubMed ID: 15374945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
    Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
    J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
    Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
    J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
    Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
    Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse DDA3 gene is a direct transcriptional target of p53 and p73.
    Hsieh SC; Lo PK; Wang FF
    Oncogene; 2002 May; 21(19):3050-7. PubMed ID: 12082536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.
    Zaika AI; Kovalev S; Marchenko ND; Moll UM
    Cancer Res; 1999 Jul; 59(13):3257-63. PubMed ID: 10397274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
    Emmrich S; Wang W; John K; Li W; Pützer BM
    Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.
    Vikhanskaya F; Bani MR; Borsotti P; Ghilardi C; Ceruti R; Ghisleni G; Marabese M; Giavazzi R; Broggini M; Taraboletti G
    Oncogene; 2001 Nov; 20(50):7293-300. PubMed ID: 11704858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p73 is up-regulated in a subset of hepatocellular carcinomas.
    Herath NI; Kew MC; Whitehall VL; Walsh MD; Jass JR; Khanna KK; Young J; Powell LW; Leggett BA; Macdonald GA
    Hepatology; 2000 Mar; 31(3):601-5. PubMed ID: 10706549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.